Kura Oncology, INC. (KURA) — SEC Filings

Q: What are the key financial highlights for Kura Oncology, INC.?

Key financial highlights for Kura Oncology, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Kura Oncology, INC.?

Key executives at Kura Oncology, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Kura Oncology, INC. stock?

Risk factors for Kura Oncology, INC. (KURA) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Kura Oncology, INC.?

Forward-looking statements and predictions from Kura Oncology, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Kura Oncology, INC.. Recent 8-K filing on Dec 2, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Kura Oncology, INC. on SEC EDGAR

Overview

Kura Oncology, INC. (KURA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 2, 2025: Kura Oncology, Inc. filed an 8-K on December 2, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or other named entities beyond the company itself.

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Kura Oncology, INC. is neutral.

Filing Type Overview

Kura Oncology, INC. (KURA) has filed 19 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13G, 9 SC 13G/A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (40)

Kura Oncology Files 8-K: Other Events — 8-K · Dec 2, 2025 Risk: medium
Kura Oncology, Inc. filed an 8-K on December 2, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, d
8-K Filing — 8-K · Nov 13, 2025
Kura Oncology's Q3 Loss Widens Amid Soaring R&D, Despite Revenue Boost — 10-Q · Nov 4, 2025 Risk: high
Kura Oncology, Inc. reported a significant increase in collaboration revenue, reaching $50.146 million for the nine months ended September 30, 2025, compared to
Kura Oncology Files 8-K — 8-K · Oct 24, 2025 Risk: medium
Kura Oncology, Inc. filed an 8-K on October 24, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, d
Kura Oncology Files 8-K — 8-K · Oct 16, 2025 Risk: medium
Kura Oncology, Inc. filed an 8-K on October 16, 2025, reporting an event that occurred on October 15, 2025. The filing is categorized under 'Other Events' and '
Kura Oncology's Q2 Loss Widens Amid Rising R&D Costs — 10-Q · Aug 7, 2025 Risk: high
Kura Oncology, Inc. reported a net loss of $43.9 million for the three months ended June 30, 2025, an increase from a net loss of $38.7 million in the prior-yea
Kura Oncology Enters Material Definitive Agreement — 8-K · Jul 1, 2025 Risk: medium
On June 27, 2025, Kura Oncology, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its counte
Kura Oncology Files 8-K — 8-K · Jun 18, 2025 Risk: medium
Kura Oncology, Inc. filed an 8-K on June 18, 2025, reporting an event that occurred on June 12, 2025. The filing pertains to 'Other Events' and 'Financial State
Kura Oncology Files 8-K on Officer/Director Changes — 8-K · Jun 6, 2025 Risk: medium
Kura Oncology, Inc. filed an 8-K on June 6, 2025, reporting on several key events that occurred on June 5, 2025. These include the departure of directors or cer
Kura Oncology Files 8-K — 8-K · Jun 3, 2025 Risk: low
Kura Oncology, Inc. filed an 8-K on June 3, 2025, reporting other events and financial statements as of June 1, 2025. The filing does not contain specific detai
Kura Oncology Files Q1 2025 10-Q — 10-Q · May 1, 2025 Risk: medium
Kura Oncology, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business operations, including de
Kura Oncology DEF 14A: Executive Compensation Details — DEF 14A · Apr 11, 2025 Risk: low
Kura Oncology, Inc. filed a DEF 14A on April 11, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity
10-K Filing — 10-K · Feb 28, 2025
Kura Oncology Files 8-K for Operations Update — 8-K · Feb 26, 2025 Risk: low
Kura Oncology, Inc. filed an 8-K on February 26, 2025, to report on its results of operations and financial condition. The filing does not contain specific fina
Kura Oncology Files 8-K — 8-K · Feb 5, 2025 Risk: low
Kura Oncology, Inc. filed an 8-K on February 5, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is located at 1273
Kura Oncology Enters Material Definitive Agreement — 8-K · Jan 14, 2025 Risk: medium
On January 13, 2025, Kura Oncology, Inc. entered into a material definitive agreement, which also created a direct financial obligation for the company. The spe
Kura Oncology Announces Board and Executive Changes — 8-K · Jan 6, 2025 Risk: low
Kura Oncology, Inc. announced on January 1, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elected n
Kura Oncology Files 8-K — 8-K · Dec 20, 2024 Risk: medium
Kura Oncology, Inc. filed an 8-K on December 20, 2024, reporting an event that occurred on December 16, 2024. The filing is a current report and does not specif
SC 13G Filing — SC 13G · Dec 5, 2024
Kura Oncology Enters Material Definitive Agreement — 8-K · Nov 20, 2024 Risk: medium
On November 20, 2024, Kura Oncology, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offic
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
Kura Oncology Q3 2024: Financials and Investments — 10-Q · Nov 7, 2024 Risk: medium
Kura Oncology, Inc. reported its third quarter 2024 results, ending September 30, 2024. The company's financial statements show significant cash and cash equiva
Kura Oncology Appoints New CMO, CSO, and Directors — 8-K · Sep 17, 2024 Risk: medium
Kura Oncology, Inc. announced on September 13, 2024, changes in its executive team and board of directors. Specifically, Dr. Michael J. Grey was appointed as Ch
Kura Oncology Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
Kura Oncology, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and operational updates. Key financial figures in
Kura Oncology Announces Board, Officer, and Compensation Changes — 8-K · Jun 7, 2024 Risk: medium
Kura Oncology, Inc. announced on June 5, 2024, a series of significant corporate changes. These include the election of new directors, the appointment of new of
Menarini Group to Acquire Kura Oncology for $1.1 Billion — 8-K · May 24, 2024 Risk: medium
Kura Oncology, Inc. announced on May 24, 2024, that it has entered into a definitive agreement to be acquired by Menarini Group. The transaction is valued at ap
SC 13G Filing — SC 13G · May 2, 2024
Kura Oncology, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: low
Kura Oncology, Inc. (KURA) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Kura Oncology, Inc. filed a 10-Q report for the period ending March 31,
Kura Oncology Announces 2024 Annual Meeting of Stockholders on June 5 — DEF 14A · Apr 12, 2024 Risk: low
Kura Oncology, Inc. (KURA) filed a Proxy Statement (DEF 14A) with the SEC on April 12, 2024. Kura Oncology, Inc. will hold its 2024 Annual Meeting of Stockholde
Kura Oncology Files 2023 Annual Report on Form 10-K — 10-K · Feb 27, 2024 Risk: medium
Kura Oncology, Inc. (KURA) filed a Annual Report (10-K) with the SEC on February 27, 2024. Kura Oncology, Inc. filed its annual report on Form 10-K for the fisc
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
Deerfield Mgmt Cuts Kura Oncology Stake to 5.0% — SC 13G/A · Feb 12, 2024 Risk: medium
Deerfield Mgmt, L.P. filed an amended SC 13G/A on February 12, 2024, indicating a change in their beneficial ownership of Kura Oncology, Inc. common stock as of
Kura Oncology Files 8-K: Corporate Info Update, Nasdaq Listing Confirmed — 8-K · Jan 30, 2024
Kura Oncology, Inc. filed an 8-K on January 30, 2024, to update its corporate information, including its address at 12730 High Bluff Drive, Suite 400, San Diego
Kura Oncology Reports Material Agreement & Unregistered Equity Sales — 8-K · Jan 26, 2024
Kura Oncology, Inc. filed an 8-K on January 26, 2024, reporting an event on January 24, 2024, concerning an entry into a material definitive agreement and unreg
BlackRock Amends Kura Oncology Stake, Signals Portfolio Adjustment — SC 13G/A · Jan 24, 2024
BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating a change in its ownership of Kura Oncology Inc. common stock as of December 31, 2023. T
State Street Corp. Maintains Significant Passive Stake in Kura Oncology — SC 13G/A · Jan 23, 2024
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 23, 2024, indicating its ownership of Kura Oncology, Inc. common s

Risk Profile

Risk Assessment: Of KURA's 26 recent filings, 2 were flagged as high-risk, 17 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Kura Oncology, INC.'s most recent 10-Q filing (Nov 4, 2025):

Revenue: $50.146M
Net Income: -$197.667M
EPS: -$0.85
Debt-to-Equity: N/A
Cash Position: $95.287M
Operating Margin: N/A
Total Assets: N/A
Total Debt: N/A

Key Executives

Chief Executive Officer
President
Dr. Michael J. Grey
Dr. Steven M. De Jong
Ms. Sarah E. Kelly
Mr. David M. R. Johnson
James E Flynn

Industry Context

The biotechnology sector, particularly oncology, is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies like Kura Oncology are focused on developing novel therapies, often through complex clinical trials. Success is highly dependent on clinical efficacy, safety, and regulatory approval, with a competitive landscape driven by innovation and strategic partnerships.

Top Tags

8-k (4) · 8-K (4) · regulatory-filing (4) · financials (4) · Biotechnology (3) · governance (3) · 10-Q (3) · Kura Oncology (3) · institutional-ownership (3) · other-events (2)

Key Numbers

Collaboration Revenue: $50.146M — for nine months ended Sep 30, 2025, up from $0 in 2024
Net Loss: $197.667M — for nine months ended Sep 30, 2025, widened from $154.766M in 2024
Research and Development Expenses: $186.666M — for nine months ended Sep 30, 2025, up from $117.700M in 2024
Cash and Cash Equivalents: $95.287M — as of Sep 30, 2025, down from $224.462M at Dec 31, 2024
Net Cash Used in Operating Activities: $181.331M — for nine months ended Sep 30, 2025
Total Stockholders' Equity: $242.542M — as of Sep 30, 2025, down from $413.640M at Dec 31, 2024
Shares Outstanding: 87,017,518 — as of Oct 31, 2025
Net Loss Per Share (Q3 2025): $0.85 — for the three months ended Sep 30, 2025
R&D Expense: $38.7M — Up from $33.9M in Q2 2024, driven by clinical trial advancements for ziftomenib and tipifarnib.
Cash and Equivalents: $350.0M — As of June 30, 2025, providing liquidity for ongoing operations.
Accumulated Deficit: $800.0M — As of June 30, 2025, highlighting historical losses.
Commission File Number: 001-37620 — Identifies Kura Oncology's SEC filing history.
IRS Employer Identification No.: 61-1547851 — Tax identification for Kura Oncology.
Reporting Period End Date: 2025-03-31 — Indicates the end of the financial quarter being reported.
Reporting Period Start Date: 2025-01-01 — Indicates the start of the financial quarter being reported.

Forward-Looking Statements

{"claim":"Kura Oncology's stock price may experience short-term volatility due to the reduction in institutional ownership.","entity":"Kura Oncology, Inc.","targetDate":"Q1 2024","confidence":"medium"}
{"claim":"Other institutional investors might re-evaluate their positions in Kura Oncology following Deerfield's reduced stake.","entity":"Institutional Investors","targetDate":"Q2 2024","confidence":"medium"}

Frequently Asked Questions

What are the latest SEC filings for Kura Oncology, INC. (KURA)?

Kura Oncology, INC. has 40 recent SEC filings from Jan 2024 to Dec 2025, including 19 8-K, 9 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of KURA filings?

Across 40 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 35 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Kura Oncology, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Kura Oncology, INC. (KURA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Kura Oncology, INC.?

Key financial highlights from Kura Oncology, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for KURA?

The investment thesis for KURA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Kura Oncology, INC.?

Key executives identified across Kura Oncology, INC.'s filings include Chief Executive Officer, President, Dr. Michael J. Grey, Dr. Steven M. De Jong, Ms. Sarah E. Kelly and 2 others.

What are the main risk factors for Kura Oncology, INC. stock?

Of KURA's 26 assessed filings, 2 were flagged high-risk, 17 medium-risk, and 7 low-risk.

What are recent predictions and forward guidance from Kura Oncology, INC.?

Recent forward-looking statements from Kura Oncology, INC. include guidance on {"claim":"Kura Oncology's stock price may experience short-term volatility due to the reduction in institutional ownersh and 1 other predictions.